Atorvastatin Calcium Patent Expiration
Atorvastatin Calcium is used for reducing LDL-C levels in patients with homozygous familial hypercholesterolemia. It was first introduced by Upjohn Manufacturing Ireland Unltd
Atorvastatin Calcium Patents
Given below is the list of patents protecting Atorvastatin Calcium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Atorvaliq | US11369567 | Aqueous suspension suitable for oral administration | Jun 07, 2037 | Cmp Dev Llc |
| Atorvaliq | US11654106 | Aqueous suspension suitable for oral administration | Jun 07, 2037 | Cmp Dev Llc |
| Atorvaliq | US11925704 | Aqueous suspension suitable for oral administration | Jun 07, 2037 | Cmp Dev Llc |
| Atorvaliq | US12168069 | Aqueous suspension suitable for oral administration | Jun 07, 2037 | Cmp Dev Llc |
| Atorvaliq | US12370136 | Aqueous Suspension Suitable For Oral Administration | Jun 07, 2037 | Cmp Dev Llc |
| Atorvaliq | US12599553 | Aqueous Suspension Suitable For Oral Administration | Jun 07, 2037 | Cmp Dev Llc |
| Lipitor |
US5969156 (Pediatric) | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan 08, 2017
(Expired) | Upjohn |
| Lipitor | US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul 08, 2016
(Expired) | Upjohn |
| Lipitor |
US5686104 (Pediatric) | Stable oral CI-981 formulation and process of preparing same |
May 11, 2015
(Expired) | Upjohn |
| Lipitor | US5686104 | Stable oral CI-981 formulation and process of preparing same |
Nov 11, 2014
(Expired) | Upjohn |
| Lipitor |
US6126971 (Pediatric) | Stable oral CI-981 formulation and process for preparing same |
Jul 19, 2013
(Expired) | Upjohn |
| Lipitor | US6126971 | Stable oral CI-981 formulation and process for preparing same |
Jan 19, 2013
(Expired) | Upjohn |
Atorvastatin Calcium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Atorvastatin Calcium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity | The United Bio-Technology (Hengqin) Co., Ltd. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants | Shandong Suncadia Medicine Co., Ltd. | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1 |
| PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |